Progress by Development
Develop & incorporate new technology and by doing so creating progress
RPMotion: the new standard for organoid culture
About
Orgonex B.V. is a pioneering Dutch biotechnology company, headquartered in Utrecht, that was founded in 2023 as a spin-off of Utrecht University by Dr. Kerstin Schneeberger and Dr. Bart Spee. Kerstin and Bart are both staff members of Utrecht University working on the creation of physiologically relevant in vitro liver models using biofabrication technology.
Mission
Create groundbreaking hardware solutions in the field of organoid technology by reducing the effort of the current culturing methods in a sustainable way and continue to work on innovative solutions in this area together with our strategic partners.
Vision
Bringing the best organoid technology to the whole Life Sciences field.
"We are Orgonex, pioneers in organoid research."
- Bart Spee, co-founder of Orgonex
Orgonex’ first product release – RPMotion
We are excited to share that Orgonex will be releasing the RPMotion bioreactor for organoid culture soon. This first and major step will usher in an era of great efficiency, quality, effectiveness and speed in the field of organoid culturing. Our patented invention of hardware technology in combination with proven protocols will change the way we culture organoids. A lot more can be achieved still so additional testing is being done as we speak.
If you are interested in joining our test and research activities, please reach out to us through a message on the contact page, stating how you think you could participate. Meanwhile Orgonex is already looking past the horizon to create and improve technical equipment and protocols advancing in niches within the field of life science. Based on market data and customer feedback, we can expand our bioreactors to large-scale bioreactors and will focus on the development of additional medical devices supporting the workflow of organoid modeling.
Meet the team
Our team comprises three seasoned experts with extensive backgrounds in stem cell biology, tissue engineering, and 3D cell culture systems. With decades of combined experience, we specialize in the development, optimization, and application of organoid models for both basic research and translational science. Our collaborative approach integrates cutting-edge techniques in organoid culture, imaging, and molecular analysis to drive innovation in disease modeling, drug screening, and regenerative medicine.
managing director
Marleen van Nuenen, PhD
Marleen holds a PhD in Gastroenterology from the Erasmus University Medical Center in Rotterdam, NL. She brings a wealth of experience to Orgonex, having held various leadership roles in the life sciences industry at organizations such as TNO, Danone, Abbott, BioConnection, Eurofins BioPharma, Cerba Research, and Ardena. Marleen has a proven track record in both managerial and commercial roles, adeptly serving high-demand clients throughout different stages of drug development.
Co-founder | Scientific advisor
Kerstin Schneeberger, PhD
Kerstin, assistant professor at Utrecht University, is a biotechnologist by training and a researcher in the field of Stem Cells and Regenerative Medicine. She has extensive expertise in stem cell biology of the gastrointestinal tract, and applied adult stem cell derived organoids as disease models and for regenerative purposes. She combined her expertise in adult stem cell derived organoids with her biotechnological background to develop new organoid technologies, such as bioreactors for large-scale organoid expansion and synthetic hydrogels for clinical applications of organoids. Her focus is on whole-organ tissue engineering as an alternative to scarce donor organs for end-stage liver disease patients. She has published more than 20 papers in high-impact journals and has been awarded with several prestigious research grants and prizes.
Co-founder | CTO
Bart Spee, PhD
As associated professor at Utrecht University, Bart has more than 18 years’ experience in Molecular Biology and Veterinary Medicine and is (co)author of over 70 peer-reviewed scientific publications. He is investigating the use of stem cells, ranging from adult stem cells (organoids) to mesenchymal stem cells and induced pluripotent stem cells (iPS) for functional recovery of liver diseases. One of the main focus points of the research is the transplantation of adult stem cells, and another primary focus is the creation of physiologically relevant in vitro liver models using biofabrication technology that can be used for drug toxicity testing and personalized medicine approaches.
Part of the Demcon group
Demcon was created as a result of the passion of its founders for solving challenging technological and social problems. We develop high-quality, innovative, complex systems and products, and can also take care of production ourselves. This way we create value for our customers. In a society faced by major challenges, we carry out projects that have a positive impact on people and the world they live in. We work on smart applications in various sectors, such as healthcare, safety, water, energy, production and communication. In addition to technological innovation we also devote our efforts to promoting entrepreneurship and investing in talent and education.
Teamwork
When people work together, they can create something greater than themselves as individuals
.jpg)
Customer satisfaction
Satisfy our customers with innovative technology and superior quality, value and service
Want to join the team?
We’re always looking for ambitious, enthusiastic, and entrepreneurial people to strengthen our team. If that sounds like you, get in touch and tell us what sets you apart. We’d love to hear how you can make a unique impact.